Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC
Clinical trial NCT02109653 · WITHDRAWN
Trial details
- NCT number
- NCT02109653
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-06-01
- Primary completion
- 2017-11-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.